Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Karn

Showing results (81-90 of 106) with videos related to

Pageof 11
Sort By:
Breast Cancer Research : BCR|December 13, 2019
Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapyBruno Valentin Sinn, Karsten E Weber, Wolfgang Daniel Schmitt, et al.
BMC Cancer|October 4, 2022
EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapyJonas Leichsenring, Valentina Vladimirova, Christine Solbach, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2022
Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast CancerKim R M Blenman, Michal Marczyk, Thomas Karn, et al.
Signal Transduction and Targeted Therapy|March 21, 2025
Targeting PI3K inhibitor resistance in breast cancer with metabolic drugsNiklas Gremke, Isabelle Besong, Alina Stroh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2025
RAD51 Testing in Patients with Early HER2-Negative Breast Cancer and Homologous Recombination Deficiency: A Post Hoc Analysis of the GeparOLA TrialGuillermo Villacampa, Alba Llop-Guevara, Natalie Filmann, et al.
Plos One|August 26, 2020
MGMT promoter methylation in triple negative breast cancer of the GeparSixto trialPaul Jank, Claire Gehlhaar, Lederer Bianca, et al.
Plos One|September 1, 2021
Correction: MGMT promoter methylation in triple negative breast cancer of the GeparSixto trialPaul Jank, Claire Gehlhaar, Bianca Lederer, et al.
Journal for Immunotherapy of Cancer|November 17, 2020
Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBCChiara Massa, Thomas Karn, Carsten Denkert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 2, 2013
Ki67 measured after neoadjuvant chemotherapy for primary breast cancerGunter von Minckwitz, Wolfgang D Schmitt, Sibylle Loibl, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2021
Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast CancerBruno V Sinn, Sibylle Loibl, Claus A Hanusch, et al.
Pageof 11

Showing results (81-90 of 106) with videos related to

Sort By:
Pageof 11
Breast Cancer Research : BCR|December 13, 2019
Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapyBruno Valentin Sinn, Karsten E Weber, Wolfgang Daniel Schmitt, et al.
BMC Cancer|October 4, 2022
EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapyJonas Leichsenring, Valentina Vladimirova, Christine Solbach, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2022
Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast CancerKim R M Blenman, Michal Marczyk, Thomas Karn, et al.
Signal Transduction and Targeted Therapy|March 21, 2025
Targeting PI3K inhibitor resistance in breast cancer with metabolic drugsNiklas Gremke, Isabelle Besong, Alina Stroh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2025
RAD51 Testing in Patients with Early HER2-Negative Breast Cancer and Homologous Recombination Deficiency: A Post Hoc Analysis of the GeparOLA TrialGuillermo Villacampa, Alba Llop-Guevara, Natalie Filmann, et al.
Plos One|August 26, 2020
MGMT promoter methylation in triple negative breast cancer of the GeparSixto trialPaul Jank, Claire Gehlhaar, Lederer Bianca, et al.
Plos One|September 1, 2021
Correction: MGMT promoter methylation in triple negative breast cancer of the GeparSixto trialPaul Jank, Claire Gehlhaar, Bianca Lederer, et al.
Journal for Immunotherapy of Cancer|November 17, 2020
Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBCChiara Massa, Thomas Karn, Carsten Denkert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 2, 2013
Ki67 measured after neoadjuvant chemotherapy for primary breast cancerGunter von Minckwitz, Wolfgang D Schmitt, Sibylle Loibl, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2021
Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast CancerBruno V Sinn, Sibylle Loibl, Claus A Hanusch, et al.
Pageof 11